Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 18/20 | 0.80 |
| ▸ | GCGR | P47871 | 9/20 | 0.80 |
| ▸ | GIPR | P48546 | 9/20 | 0.75 |
| ▸ | CCKBR | P32239 | 2/20 | 0.73 |
| ▸ | NPY1R | P25929 | 1/20 | 0.72 |
| ▸ | NPY2R | P49146 | 1/20 | 0.72 |
| ▸ | NPY4R | P50391 | 1/20 | 0.72 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307619 | 1.00 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBRNPY1R | |
| SCHEMBL29367539 | 0.99 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBRNPY1R | |
| SCHEMBL29367233 | 0.99 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBRNPY1R | |
| SCHEMBL29364819 | 0.96 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL30645490 | 0.95 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL29576071 | 0.95 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL30460356 | 0.95 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL30473764 | 0.95 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL30473786 | 0.95 | GLP1R (0.79) | GLP1RGCGRGIPRCCKBRNPY1R | |
| SCHEMBL30473790 | 0.95 | GLP1R (0.79) | GLP1RGCGRGIPRCCKBRNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819551-A | GLP-1/glucagon/gastrin receptor triple agonist with site-specific modification and application thereof | 南京赛诺生物制药有限公司 | 2023-03-21 | — | — | CN | claimed |